Clinical trials: Psoriasis Arthritis
Psoriatic Arthritis
Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.
The purpose of this study was to assess the efficacy and safety of secukinumab in Chinese participants with active Psoriatic arthritis (PsA ) compared to placebo.
- Trial name
- NCT04711902
- Testing
- AIN457
- Where
- 12 sites in China
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis (ASAP Study)
This was a randomized, open, parallel, controlled, multi-center, interventional, cross-sectional study to evaluate the detection rate of Psoriatic arthritis (PsA) in Korean moderate to severe Psoriasis (PsO) patients with or…
- Trial name
- ASAP (NCT05758402)
- Testing
- Routine practice group, EARP group
- Where
- 15 sites in South Korea
- Volunteers
- 368 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
- Trial name
- NCT03158285
- Testing
- Guselkumab
- Where
- 138 sites in United States, Bulgaria and 11 more
- Volunteers
- 741 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an…
- Trial name
- OPAL BROADEN (NCT01877668)
- Testing
- Tofacitinib 5 mg BID, Tofacitinib 10 mg BID, Adalimumab
- Where
- 123 sites in United States, Australia and 14 more
- Volunteers
- 422 people
- Sponsor
- Pfizer
Psoriatic Arthritis
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
The purpose of this study was to demonstrate efficacy including effect on inhibition of progression of structural damage, safety and tolerability up to 2 years with primary focus at Week 16 (week 24 for structural damage), to…
- Trial name
- FUTURE5 (NCT02404350)
- Testing
- Secukinumab
- Where
- 172 sites in United States, Argentina and 26 more
- Volunteers
- 997 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis
This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active Psoriatic Arthritis (PsA).
- Trial name
- NCT05153148
- Testing
- NDI-034858
- Where
- 56 sites in United States, Czechia and 2 more
- Volunteers
- 305 people
- Sponsor
- Takeda
Inflammatory Bowel Diseases
Regulation of Mucosal Healing in Inflammatory Bowel Disease
The objective of the current study is to compare non-healing colonic ulcers in patients with inflammatory bowel disease (IBD) with iatrogenic colonic ulcers (biopsy sites) in healthy control patients and patients with rheumatoid…
- Trial name
- NCT04504136
- Testing
- Serial Biopsy
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Terrence A Barrett
Rheumatoid Arthritis, Psoriasis Arthritis
Prospective Evaluation of the Radiographic Efficacy of Enbrel
It is known from the COMET-trial that patients who start Enbrel treatment early have a great chance of reaching clinical remission and radiographic nonprogression.
- Trial name
- PRERA (NCT01623752)
- Testing
- Etanercept
- Volunteers
- 1,821 people
- Sponsor
- Pfizer
Psoriatic Arthritis
Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice
This study is a documentation of effectiveness and safety of Humira in patients with psoriatic arthritis.
- Trial name
- NCT01111240
- Where
- 509 sites in Germany
- Volunteers
- 4,635 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Arthritis
The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis
Background: There is evidence for a high cardiovascular risk in rheumatic and inflammatory diseases . Recent evidence suggest that psoriatic arthritis is also associated with an increased cardiovascular risk with accelerated…
- Trial name
- NCT01818804
- Testing
- n-3PUFA, olive oil
- Where
- 2 sites in Denmark
- Volunteers
- 145 people
- Sponsor
- Aalborg University Hospital
Rheumatoid Arthritis, Psoriasis
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly…
- Conditions
- Rheumatoid Arthritis, Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Diseases
- Trial name
- NCT03329885
- Testing
- BMS-986251
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis, Psoriatic Arthritis
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650 at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom effect of the treatment was confirmed after the treatment…
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Pustular Psoriasis (Excluding a Localized), Psoriatic Erythroderma
- Trial name
- NCT01680159
- Testing
- TA-650
- Where
- 7 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Tanabe Pharma Corporation
Arthritis, Psoriatic
Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis
The aim of this study is to evaluate if the data obtained in controlled clinical trials are confirmed when Enbrel is used in usual clinical practice in Belgium according to local reimbursement criteria.
- Trial name
- PROVE (NCT00938015)
- Testing
- Questionnaire
- Where
- Belgium
- Volunteers
- 303 people
- Sponsor
- Pfizer
Arthritis, Psoriatic
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
The purpose of this study was to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and…
- Trial name
- FUTURE 4 (NCT02294227)
- Testing
- Secukinumab
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 341 people
- Sponsor
- Novartis Pharmaceuticals
Axial Psoratic Arthritis
Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 150 mg or 300 mg in the management of axial manifestations in PsA patients who have failed to respond to at least 2 non-steroidal…
- Trial name
- MAXIMISE (NCT02721966)
- Testing
- Secukinumab
- Where
- 94 sites in Belgium, Bulgaria and 16 more
- Volunteers
- 503 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis
The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.
- Trial name
- NCT00267956
- Testing
- CNTO 1275 63 mg
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 146 people
- Sponsor
- Centocor, Inc.
Arthritis
Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis
The purpose of this research study is to see if patients with juvenile idiopathic arthritis or seronegative arthritis (and related conditions) mount protective immune responses to the human papillomavirus (HPV) vaccine called…
- Trial name
- CHASE (NCT00573651)
- Testing
- Blood Draws for Serum Titers
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- University Hospitals Cleveland Medical Center
Ankylosing Spondylitis, Arthritis, Psoriatic
Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis
This is a Phase 4 open label, non-interventional, multi-center study to evaluate the safety of Enbrel (etanercept) treatment in patients receiving etanercept 25mg sc twice weekly or 50mg of etanercept once weekly.
- Conditions
- Ankylosing Spondylitis, Arthritis, Psoriatic, Arthritis, Rheumatoid, Spondylitis, Ankylosing
- Trial name
- NCT00273858
- Testing
- There is no Intervention. The study is observational.
- Where
- 9 sites in Greece
- Volunteers
- 880 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Arthritis, Psoriatic
Study Evaluating the Safety of Enbrel (Etanercept)
The purpose of this study is to collect post-marketing information on the safety of Enbrel in Filipino patients.
- Trial name
- NCT00683384
- Testing
- Etanercept (Enbrel)
- Where
- Philippines
- Volunteers
- 93 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriatic Arthritis
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE 1 (NCT03675308)
- Testing
- Risankizumab
- Where
- 256 sites in United States, Argentina and 37 more
- Volunteers
- 964 people
- Sponsor
- AbbVie